Human immunodeficiency virus 1 protease inhibitors in clinical practice: Predictors of virological outcome

Archives of Internal Medicine

Volumn 159, Issue 15, 1999, Pages 1771-1776

  Valdez, Hernan ^a,b,d   Lederman, Michael M ^a,b   Woolley, Ian ^b   Walker, Courtney J ^a   Vernon, Lance T ^c   Hise, Amy ^b   Gripshover, Barbara M ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CONSULTATION; DISEASE COURSE; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0033598112     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.15.1771     Document Type: Article

References (28)

1. Carr A, Marriott D, Field A, Vasak E, Cooper DA. Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combined antiretroviral therapy. Lancet. 1998;351:256-261.
2. Sepkowitz KA. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet. 1998;351:228-230.
3. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
4. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS. 1997;11:F101-F105.
5. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med. 1996;334:1011-1017.
6. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic milliliter or less. N Engl J Med. 1997; 337:725-733.
7. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet. 1998;351:543-549.
8. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996; 272:1167-1170.
9. + lymphocyte counts and the risk of progression to AIDS. N Engl J Med. 1996; 334:426-431.
10. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA. 1998;280:78-86.
11. Feinberg MB, Carpenter C, Fauci AS, et al. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Ann Intern Med. 1998;128:12(pt 2): 1057-1100.
12. Gulick RM, Mellors JW, Havlir D, et al. Simultaneous versus sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA. 1998;280:35-41.
13. Falkenheuer G, Theisen A, Rockstroh J, et al. Virologic treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS. 1997;11:F113-F116.
14. Deeks S, Loftus R, Cohen P, Chin S, Grant R. Incidence and predictors of virologic failure to indinavir and/or ritonavir in an urban health clinic. Presented at: the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Canada. Abstract LB-2.
15. Montaner JSG, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. JAMA. 1998;279:930-937.
16. Kernpf DJ, Rode RA, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS. 1998;12:F9-F14.
17. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viremic with highly active antiretroviral therapy (HAART). Lancet. 1998;351:723-724.
18. Zennou V, Mammano F, Paulous S, Mathez D, Clavel F. Loss of viral fitness associated with multiple gag and gag-pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol. 1998;72:3300-3306.
19. Currier JS, Williams PL, Grimes JM, Squires KS, Fischl MA, Hammer SM. Incidence rates and risk factors for opportunistic infections in a phase III trial comparing indinavir+ZDV+3TC to ZDV+3TC. Presented at: the 5th Conference on Retroviruses and Opportunistic Infections; February 3, 1998; Chicago, III. Abstract 257.
20. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med. 1996;335:1091-1098.
21. Webber MP, Schoenbaum EE, Gourevitch MN, Buono D, Klein RS. A prospective cohort study: HIV disease progression among drug users by gender. Presented at: the 5th Conference on Retroviruses and Opportunistic Infections; February 2, 1998; Chicago, III. Abstract 209.
22. Anonymous. Projections of the number of persons diagnosed with AIDS and the number of immunosuppressed HIV-infected persons - United States, 1992-1994. MMWP Morb Mortal Wkly Rep. 1992;41:2-23.
23. Hecht FM, Colfax G, Swanson M, Chesney MA. Adherence and effectiveness of protease inhibitors in clinical practice. Presented at: the 5th Conference on Retroviruses and Opportunistic Infections; February 2, 1998; Chicago, III. Abstract 151.
24. Tebas P, Royal M, Fichtenbaum C, et al. Relationship between adherence to HAART and disease state. Presented at: the 5th Conference on Retroviruses and Opportunistic Infections; February 2, 1998; Chicago, III. Abstract 149.
25. Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF. Patient compliance and drug failure in protease inhibitor monotherapy [letter]. JAMA. 1996; 276:1955-1956.
26. Flexner C. HIV-protease inhibitors. N Engl J Med. 1998;338:1281-1292.
27. Hertogs K, Mellors JW, Schel P, et al. Patterns of cross-resistance among protease inhibitors in 483 clinical HIV-1 isolates. Presented at: the 5th Conference on Retroviruses and Opportunistic Infections; February 3, 1998; Chicago, III. Abstract 395.
28. Hogg RS, Rhone SA, Yip B, et al. Antiviral effect of double and triple drug combinations amongst HIV-infected adults: lessons from the implementation of viral load-driven antiretroviral therapy. AIDS. 1998;12:279-284.